Article Text
Statistics from Altmetric.com
Description
A 74-year-old man with metastatic gastro-oesophageal adenocarcinoma involving coeliac lymph nodes and liver was treated with fluorouracil and oxaliplatin (FOLFOX) chemotherapy. Despite initial good response, Oxaliplatin was omitted after development of significant peripheral neuropathy. His subsequent imaging showed progression of disease, predominantly in the liver. Selective internal radionuclide therapy (SIRT–Yttrium-90 (90Y) resin microsphere radioembolisation) was chosen by the multidisciplinary team as the modality to target his dominant left hepatic lobar disease.
90Y is a β-particle emitter suitable for radionuclide therapy, which, until recently, was not thought to be able to provide images directly from the decay of the radionuclide.1 Pretreatment (18F) fludeoxyglucose positron emission tomography (FDG PET)/CT demonstrated increased glucose metabolism in the rim of the large left lobe lesion. After informed consent, 810 MBq (90Y)-microspheres were injected into the left hepatic artery, using selective catheterisation. Approximately 18 hours postradioembolisation a 90Y PET/CT scan confirmed good deposition of the radiolabelled microspheres around the lesion from which the dose of radiation could be derived. Follow-up (18F)-FDG PET/CT scan taken 11 weeks after the intervention demonstrated a very good response with markedly reduced metabolic activity (figure 1). There was no progression of the left lobe lesion for 15 months.
The high sensitivity PET/CT scanner used allows acquisition of (18F)-FDG and the technically challenging 90Y images. 90Y images are more difficult to capture due to very low radiation flux available for imaging from 90Y decay (32 ppm); this has been demonstrated previously.2 Liver directed SIRT is an emerging new treatment modality for patients with metastatic gastrointestinal cancers, which was recently shown to delay disease progression in the liver.3 Here we have shown that multitracer PET allows accurate dosimetry and therapeutic monitoring in a single imaging platform, and should be considered in future investigations of this treatment.
Learning points
High sensitivity positron emission tomography/CT scanners can acquire standard (18F)-fludeoxyglucose and Yttrium-90 (90Y) images to accurately record dose delivery and treatment response following selective internal radionuclide therapy.
Durable response was achieved with (90Y)-microsphere radionuclide therapy in liver metastasis arising from gastro-oesophageal adenocarcinoma—a therapeutic option for isolated liver metastasis in patients who are otherwise unsuitable for aggressive surgical intervention.
Footnotes
Contributors DB contributed to the development of the initial manuscript drafts and acquisition of de-identified images for the case. AL and BTL contributed to manuscript reviews and final preparations. SC provided overall supervision of the manuscript design and final approval.
Funding BTL is supported by a Cancer Centre Core Grant (P30 CA008748) at Memorial Sloan Kettering Cancer Center, from the National Institutes of Health, USA.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.